Cancer vaccine CEA-TRICOM - Sanofi/Therion Biologics
Alternative Names: CEA-TRICOMLatest Information Update: 04 Apr 2022
Price :
$50 *
At a glance
- Originator National Cancer Institute (USA); Therion Biologics
- Developer Georgetown University; National Cancer Institute (USA); Therion Biologics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Pancreatic cancer
Most Recent Events
- 08 Mar 2005 Discontinued - Phase-I for Colorectal cancer in USA (unspecified route)
- 08 Mar 2005 Discontinued - Phase-I for Pancreatic cancer in USA (unspecified route)
- 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur